CytoDyn (CYDY)
(Delayed Data from OTC)
$0.16 USD
0.00 (0.92%)
Updated Sep 19, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for CytoDyn Inc falls in the month of May.
All items in Millions except Per Share data.
5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 9 | 4 | 34 | 14 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 93 | 19 |
Other Current Assets | 1 | 2 | 6 | 2 | 3 |
Total Current Assets | 11 | 11 | 11 | 130 | 37 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 18 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 2 | 13 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 11 | 11 | 29 | 132 | 51 |
Liabilities & Shareholders Equity | 5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 |
---|---|---|---|---|---|
Notes Payable | 30 | 34 | 36 | 63 | 7 |
Accounts Payable | 30 | 63 | 68 | 66 | 29 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 25 | 23 | 19 | 24 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 84 | 120 | 123 | 153 | 45 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 8 |
Long-Term Debt | 0 | 1 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 44 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 128 | 121 | 124 | 153 | 53 |
Shareholders Equity | 5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 774 | 731 | 671 | 490 | 352 |
Retained Earnings | -892 | -842 | -766 | -511 | -355 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -117 | -110 | -94 | -21 | -2 |
Total Liabilities & Shareholder's Equity | 11 | 11 | 29 | 132 | 51 |
Total Common Equity | -117 | -110 | -94 | -21 | -2 |
Shares Outstanding | 1,017.60 | 921.10 | 723.80 | 620.70 | 535.20 |
Book Value Per Share | -0.11 | -0.12 | -0.13 | -0.03 | 0.00 |
Fiscal Year End for CytoDyn Inc falls in the month of May.
All items in Millions except Per Share data.
8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 10 | 8 | 7 | 9 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 2 | 2 | 3 |
Total Current Assets | NA | 11 | 10 | 9 | 12 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 11 | 10 | 9 | 12 |
Liabilities & Shareholders Equity | 8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 30 | 30 | 33 | 33 |
Accounts Payable | NA | 30 | 62 | 62 | 63 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 25 | 31 | 28 | 26 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 6 | 0 | 7 |
Total Current Liabilities | NA | 84 | 129 | 123 | 129 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 128 | 130 | 124 | 129 |
Shareholders Equity | 8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 774 | 754 | 747 | 735 |
Retained Earnings | NA | -892 | -875 | -863 | -853 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -117 | -119 | -114 | -117 |
Total Liabilities & Shareholder's Equity | NA | 11 | 10 | 9 | 12 |
Total Common Equity | 0 | -117 | -119 | -114 | -117 |
Shares Outstanding | 1,214.40 | 1,017.60 | 989.40 | 978.60 | 930.40 |
Book Value Per Share | 0.00 | -0.11 | -0.12 | -0.12 | -0.13 |